Molecular Diagnostic Market by Product (Reagents & Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, INAAT, Sequencing, Microarray), Application (Infectious Diseases, Oncology), End User (Hospital, Diagnostic Lab)—Global Forecast to 2030

Molecular Diagnostic Market by Product (Reagents & Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, INAAT, Sequencing, Microarray), Application (Infectious Diseases, Oncology), End User (Hospital, Diagnostic Lab)—Global Forecast to 2030

Molecular Diagnostic Market by Product (Reagents & Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, ISH, INAAT, Sequencing, Microarray), Application (Infectious Diseases, Oncology), End User (Hospital, Diagnostic Lab)—Global Forecast to 2030.

The molecular diagnostics market is expected to reach $46.69 billion by 2030, at a CAGR of 5.6% from 2023 to 2030.

After extensive primary and secondary research, the report provides an in-depth analysis of the molecular diagnostics market. The report also provides insights into the key drivers, restraints, challenges, and opportunities in the molecular diagnostics market. The growth of this market is driven by the rising global geriatric population, the increasing prevalence of communicable & non-communicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures. However, unfavorable regulatory frameworks and the high costs of molecular diagnostic tests restrain the growth of this market. Growth opportunities in emerging countries, increasing focus on companion diagnostics, and the rising popularity of direct-to-consumer (DTC) genetic testing are expected to offer growth opportunities for the players operating in this market.

Based on product & service, in 2023, the kits & reagents segment is estimated to account for the largest share of the molecular diagnostics market. The large market share of this segment is attributed to technological advancements and increased usage of diagnostic kits in healthcare settings.

Based on test type, in 2023, the laboratory test segment is estimated to account for the largest share of the molecular diagnostics market. The large market share of this segment is attributed to its benefits, such as various activities that can be carried out in one room, such as sample processing, diagnosis, and further analysis of the results.

Based on technology, in 2023, the polymerase chain reaction (PCR) segment is estimated to account for the largest share of the molecular diagnostics market. The large market share of this segment is attributed to the advantages of the technology over others, such as the specific detection of rare DNA sequences with accuracy and the launch of advanced high throughput PCR devices.

Based on application, in 2023, the infectious diseases segment is estimated to account for the largest share of the molecular diagnostics market. The large market share of this segment is attributed to the rising prevalence of infectious diseases globally, which includes hepatitis, HIV, healthcare-associated infections (HAIs), and influenza, among others. As these are not age-specific, molecular diagnosis is required for every person affected by these infectious diseases.

Based on end user, in 2023, the hospitals & clinics segment is estimated to account for the largest share of the molecular diagnostics market. The large market share of this segment is attributed to the increase in the number of diagnostic tests done, especially during the COVID-19 pandemic, the rise in technological advancement for diagnostic platforms in hospitals, and the availability of skilled professionals.

An in-depth analysis of the geographical scenario of the molecular diagnostics market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is estimated to account for the largest share of the molecular diagnostics market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The rise in prevalence of chronic diseases, increase in venture capital funding, increase in healthcare expenditure, and presence of key companies.

The key players operating in the molecular diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), and Seegene, Inc. (South Korea).

Scope of the Report:

Global Molecular Diagnostics Market, by Product & Service

Kits & Reagents
Instruments
Software & Services

Global Molecular Diagnostics Market, by Test Type

Laboratory Tests
PoC Tests

Global Molecular Diagnostics Market, by Technology

Polymerase Chain Reaction (PCR)
In Situ Hybridization (ISH)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Microarrays
Mass Spectrometry
Sequencing
Other Technologies

Global Molecular Diagnostics Market, by Application

Infectious Diseases
COVID-19
Hepatitis
HIV
Healthcare-associated Infections (HAIs)
Chlamydia trachomatis/ Neisseria gonorrhoeae (CT/NG)
Human papillomavirus (HPV)
Tuberculosis
Influenza
Other Infectious Diseases
Oncology
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Leukemia
Cervical Cancer
Other Cancer Types
Genetic Testing
Neurological Diseases
Cardiovascular Diseases
Other Applications

Global Molecular Diagnostics Market, by End User

Hospitals & Clinics
Diagnostic Laboratories
Academic & Research Institutes
Other End Users

Global Molecular Diagnostics Market, by Geography

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific
China
Japan
India
Australia
Rest of Asia-Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (RoLATAM)
Middle East & Africa

Molecular Diagnostics Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	327
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Product, Market by Test Type Market by Technology, Market by Application, Market by End User, Market by Geography
Key Companies Mentioned	F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), and Seegene, Inc. (South Korea).

FAQs About the Report

What is the focus of the molecular diagnostics market study?

The molecular diagnostics market study covers the market sizes & forecasts for various molecular diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the molecular diagnostics market at the regional and country levels.

What is the value of revenue generated from the sale of molecular diagnostics products across the globe? At what rate is their demand expected to grow for the next 5-7 years?

The molecular diagnostics market is projected to reach $46.69 billion by 2030, at a CAGR of 5.6% during the forecast period.

Which product segment is expected to account for the largest share and register the highest growth rate in the molecular diagnostics market?

Based on product & service, in 2023, the kits & reagents segment is expected to account for the largest share of the molecular diagnostics market. This segment is also projected to register the highest CAGR during the forecast period. The fast growth rate of this segment is driven by the need for kits for the growing prevalence of diseases and the growing awareness of early diagnosis among the people.

Which end user segment is projected to create more traction in the molecular diagnostics market during the forecast period?

The diagnostic laboratories segment is slated to register the highest CAGR during the forecast period. The growth of this segment is driven by the expansion of diagnostic laboratories and the installation of advanced systems in laboratories.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the molecular diagnostics market?

The growth of this market is driven by the rising global geriatric population, the increasing prevalence of communicable & non-communicable diseases, technological advancements in molecular diagnostics, and rising healthcare expenditures.

In addition, the growing scope in emerging countries, increasing focus on companion diagnostics, and the rising popularity of direct-to-consumer (DTC) genetic testing are expected to provide significant opportunities for the growth of this market.

Who are the major players operating in the molecular diagnostics market?

The key players operating in the molecular diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), and Seegene, Inc. (South Korea).

Which regions/countries are expected to offer significant growth opportunities for the vendors operating in the molecular diagnostics market?

Emerging economies from Asia-Pacific, such as China and India, are projected to offer significant growth opportunities for vendors operating in this market due to the growing awareness about infectious diseases, focus on technological advancements, increasing geriatric population, and increasing investment in the healthcare sector.